Unichem Laboratories is currently trading at Rs. 263.00, down by 1.90 points or 0.72% from its previous closing of Rs. 264.90 on the BSE.
The scrip opened at Rs. 263.00 and has touched a high and low of Rs. 263.60 and Rs. 261.40 respectively. So far 3395 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 319.90 on 20-Oct-2016 and a 52 week low of Rs. 210.10 on 18-Mar-2016.
Last one week high and low of the scrip stood at Rs. 271.80 and Rs. 250.00 respectively. The current market cap of the company is Rs. 2388.69 crore.
The promoters holding in the company stood at 50.08%, while Institutions and Non-Institutions held 17.32% and 32.60% respectively.
Unichem Laboratories’ formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the company, correctable ones in respect of which the company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the company's supplies to the US market.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: